Compare BridgeBio Pharma Inc (BBIO) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Hut 8 Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Hut 8 Corp trades at $90.96 (market cap $10.56B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | HUT | |
|---|---|---|
Market Cap | $16.61B | $10.56B |
Sector | Health | Technology |
52-Week High | $90.17 | $133.02 |
52-Week Low | $47.29 | $21.37 |
Enterprise Value | $18.16B | $17.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
HUT trades at $88.59, down 2.27% today amid bearish technical signals and mixed quarterly earnings. The stock faces headwinds from negative net income margins and cash burn, but maintains strong analyst support with a 93.75% buy rating and a $165.11 consensus price target. Recent news highlights institutional accumulation and a strategic pivot to AI data centers, backed by a $26.6 billion contracted backlog.
Outlook hinges on execution of AI infrastructure projects, offering substantial upside if targets are met, but high valuation multiples and persistent losses pose risks. Investors must weigh growth potential against financial sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
